Adaptin Bio (APTN) Cash & Equivalents (2022 - 2026)
Adaptin Bio (APTN) posted Cash & Equivalents of $301309.0 for Q1 2026, down 34.38% sequentially from $459174.0 in Q4 2025, and down 87.31% YoY from $2.4 million in Q1 2025.
Adaptin Bio (APTN) Cash & Equivalents (2022 - 2026) Analysis & Trends
Adaptin Bio has reported Cash & Equivalents for 5 years, with the latest figure at $301309.0 in Q1 2026.
- Quarterly Cash & Equivalents fell 87.31% year-over-year to $301309.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $301309.0 (down 87.31% YoY) and the FY2025 annual result came in at $459174.0, up 1247.14% from the prior year.
- Cash & Equivalents retreated to $301309.0 in Q1 2026 per APTN's latest filing, from $459174.0 in the prior quarter.
- Over five years, Cash & Equivalents peaked at $2.4 million in Q1 2025 and troughed at $322.0 in Q3 2024.
- A 5-year average of $427849.7 and a median of $28930.5 in 2024 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2025 and 2026: Cash & Equivalents surged 179741.3% in 2025, then sank 87.31% in 2026.
- Over 5 years, Cash & Equivalents stood at $500.0 in 2022, then surged by 850.8% to $4754.0 in 2023, then soared by 616.98% to $34085.0 in 2024, then jumped by 1247.14% to $459174.0 in 2025, then plunged by 34.38% to $301309.0 in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $301309.0, $459174.0, and $579089.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 670,488.00 |
| Mar 31, 2026 | 301,309.00 |
| Dec 31, 2025 | 459,174.00 |
| Sep 30, 2025 | 579,089.00 |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 34,085.00 |
| Sep 30, 2024 | 322.00 |
| Jun 30, 2024 | 23,776.00 |
| Mar 31, 2024 | 5,059.00 |
| Dec 31, 2023 | 4,754.00 |
| Sep 30, 2023 | 380.00 |
| Dec 31, 2022 | 500.00 |